Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its PAR2 biased negative allosteric modulator program Posters...
Hence then, the article about domain therapeutics to present data on its gpcr lead programs at aacr annual meeting 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025 )
Also on site :
- China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
- Goldman Sachs expects layoffs to keep rising—and says investors are punishing the stocks of companies that slash staff
- Prominent Canadian Musician Says Gig Was Cancelled After Google AI Overview Wrongly Branded Him Sex Pest